Figure 1
From: Synthetic integrin-binding immune stimulators target cancer cells and prevent tumor formation
(A) Comparison of a typical IgG (left) and the synthetic immune system engager (ISEr) Y9 consisting of an effector (F) as well as two linker and binder (B) moieties. (B) Proposed mechanism of innate immune system activation by Y9. Upon specific binding to tumor cells, neutrophils, monocytes and macrophages are recruited to these cells and directly attack tumor cells displaying Y9. Further effects are based on cytokine release of macrophages and monocytes, recruiting other immune cells.
